Page last updated: 2024-11-05

dexbrompheniramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dexbrompheniramine is an antihistamine medication used to relieve allergy symptoms such as sneezing, runny nose, itchy eyes, and hives. It is available over-the-counter (OTC) and by prescription. Dexbrompheniramine belongs to a class of medications known as H1-receptor antagonists, which work by blocking the effects of histamine, a chemical released by the body during an allergic reaction. The synthesis of dexbrompheniramine involves several steps, starting with the reaction of 2-bromo-N,N-diethylaniline with 2-chloro-1-(2-pyridyl)propan-1-one to produce a key intermediate. This intermediate is then reacted with sodium hydroxide to form dexbrompheniramine. Dexbrompheniramine is commonly studied to understand its pharmacological effects, including its effectiveness in treating allergies, its potential side effects, and its interactions with other medications. Dexbrompheniramine is a relatively safe and effective medication for treating allergic symptoms. However, it can cause drowsiness, dizziness, and dry mouth, and it may interact with other medications.'

dexbrompheniramine : The (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16960
CHEMBL ID1201287
CHEBI ID59269
SCHEMBL ID29345
MeSH IDM0064163

Synonyms (65)

Synonym
(3s)-3-(4-bromophenyl)-n,n-dimethyl-3-(pyridin-2-yl)propan-1-amine
CHEBI:59269 ,
dexbromfeniramina
dexbrompheniraminum
PDSP1_000134
dexbrompheniramine
(3s)-3-(4-bromophenyl)-n,n-dimethyl-3-pyridin-2-ylpropan-1-amine
132-21-8
PDSP2_000133
PDSP1_000135
LOPAC0_000232
PDSP2_000134
d-brompheniramine
3-(4-bromophenyl)- n,n-dimethyl- 3-pyridin-2-yl-propan-1-amine
(r)-3-(4-bromophenyl)-3-(2-pyridyl)propyldimethylamine
(+)-brompheniraminum
DB00405
desbrofeniramina
(s)-brompheniramine
(s)-(+)-brompheniramine
einecs 205-053-5
dexbrompheniramine [inn:ban]
brompheniramine d-
dexbromfeniramina [inn-spanish]
dexbrompheniraminum [inn-latin]
NCGC00162100-01
NCGC00162100-03
CHEMBL1201287
brompheniramine, (s)-
brompheniramine d-form
CCG-204327
75t64b71rp ,
(+)-(3-p-bromphenyl-3-pyrid-2'-ylpropyl)dimethylamin
unii-75t64b71rp
(+)-n,n-dimethyl-(3-(4-bromphenyl)-3-(2-pyridyl)propyl)amin
AKOS015969654
156428-34-1
dexbrompheniramine [vandf]
dexbrompheniramine [who-dd]
brompheniramine, (+)-
dexbrompheniramine [inn]
brompheniramine d-form [mi]
gtpl7588
AB00698453-08
SCHEMBL29345
(+)-parabromdylamine
2-pyridinepropanamine, .gamma.-(4-bromophenyl)-n,n-dimethyl-, (s)-
pyridine, 2-[p-bromo-.alpha.-[2-(dimethylamino)ethyl]benzyl]-, (s)-
3-(4-bromophenyl)-n,n-dimethyl-3-(2-pyridinyl)-1-propanamine #
ZDIGNSYAACHWNL-HNNXBMFYSA-N
DTXSID8022905 ,
[(3s)-3-(4-bromophenyl)-3-(pyridin-2-yl)propyl]dimethylamine
(s)-3-(4-bromophenyl)-n,n-dimethyl-3-(pyridin-2-yl)propan-1-amine
Q5268318
(+)-brompheniramine; (+)-parabromdylamine; (s)-brompheniramine
SDCCGSBI-0050220.P002
NCGC00162100-05
EN300-25893693
dexbrompheniramin
dexbrompheniraminum (inn-latin)
dexbromfeniramina (inn-spanish)
r06ab06
dtxcid002905
()-(3-p-bromphenyl-3-pyrid-2'-ylpropyl)dimethylamin
desbromfeniramina

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" In addition, the major bioavailability parameters (Cmin, Cmax, tmax, and AUC) for days 6 and 7 of dosing were determined and statistically evaluated."( Steady-state bioavailability of dexbrompheniramine and pseudoephedrine from a repeat-action combination tablet.
Digiore, C; Gural, R; Kim, HK; Lim, J; Lin, CC; Symchowicz, S, 1985
)
0.55

Dosage Studied

ExcerptRelevanceReference
" Blood samples for subsequent assay were obtained at frequent time intervals throughout each 7-d dosing phase."( Steady-state bioavailability of dexbrompheniramine and pseudoephedrine from a repeat-action combination tablet.
Digiore, C; Gural, R; Kim, HK; Lim, J; Lin, CC; Symchowicz, S, 1985
)
0.55
"Sprague-Dawley male albino rats showed in a dose-response study a maximal drinking response to a 5 U/kg dose of SC insulin in a 2-hr test."( Histaminergic mechanism for drinking elicited by insulin in the rat.
Hecht, ES; Kraly, FS; Miller, LA, 1983
)
0.27
"25-20 mg/kg) in a dose-response study."( A probe for a histaminergic component of drinking in the rat.
Kraly, FS, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
H1-receptor antagonistH1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
anti-allergic agentA drug used to treat allergic reactions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
brompheniraminePheniramine in which the hydrogen at position 4 of the phenyl substituent is substituted by bromine. A histamine H1 receptor antagonist, brompheniramine is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Dexbrompheniramine H1-Antihistamine Action87

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.31620.100020.879379.4328AID588453
arylsulfatase AHomo sapiens (human)Potency1.90121.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency15.84890.035520.977089.1251AID504332
D(1A) dopamine receptorHomo sapiens (human)Potency3.26410.02245.944922.3872AID488982
chromobox protein homolog 1Homo sapiens (human)Potency31.62280.006026.168889.1251AID488953
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (47.06)18.7374
1990's3 (8.82)18.2507
2000's4 (11.76)29.6817
2010's6 (17.65)24.3611
2020's5 (14.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.75 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index68.22 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (45.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (13.89%)5.53%
Reviews1 (2.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]